自身免疫性肝炎患者肝细胞癌的发病率与预测因素
该多中心回顾性观察研究纳入国际自身免疫性肝炎回顾性登记队列中1980至2020年诊断的1428例患者,中位随访11.1年,24例发生肝细胞癌(1.7%),发病率为1.44例/1000患者年,累积发病率随时间升高;基线肥胖、肝硬化和AIH/PSC变异综合征是独立危险因素。
要点
- 自身免疫性肝炎患者肝细胞癌发病率低,为1.44例/1000患者年。
- 肝细胞癌累积发病率随时间升高,30年随访达6.6%。
- 基线肥胖、肝硬化及AIH/PSC变异综合征为独立危险因素。
核心结论
- 自身免疫性肝炎患者肝细胞癌发病率低,即使进展为肝硬化后仍较低,且与肥胖、肝硬化及AIH/PSC变异综合征等危险因素相关。
研究设计与样本
- 研究为回顾性、观察性、多中心研究,纳入国际自身免疫性肝炎回顾性登记队列中1980年至2020年来自欧洲和加拿大22个合格中心的1428例自身免疫性肝炎患者,中位随访11.1年(四分位距5.2-15.9)。
主要发现
- 随访期间24例(1.7%)发生肝细胞癌,发病率为1.44例/1000患者年。
- 肝细胞癌累积发病率在随访5年、10年、20年和30年时分别为0.6%、0.9%、2.7%和6.6%。
- 随访期间发生肝硬化的患者肝细胞癌发病率显著更高;肝硬化发生后5年、10年、15年和20年的肝细胞癌累积发病率分别为2.6%、4.6%、5.6%和6.6%。
- 基线肥胖(风险比[HR] 2.94,p=0.04)、肝硬化(HR 3.17,p=0.01)和AIH/PSC变异综合征(HR 5.18,p=0.007)是肝细胞癌发生的独立危险因素。
临床怎么用
- 作者认为,基于这些发现,根据患者个体危险因素采用专门的肝细胞癌监测方案似乎是有价值的。
局限性
- 原文指出,关于自身免疫性肝炎患者肝细胞癌风险的可靠数据仍难以获得,因为现有证据大多来自小型、单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Autoimmune hepatitis (AIH) is a rare chronic liver disease of unknown aetiology; the risk of hepatocellular carcinoma (HCC) remains unclear and risk factors are not well-defined. We aimed to investigate the risk of HCC across a multicentre AIH cohort and to identify predictive factors. METHODS: We performed a retrospective, observational, multicentric study of patients included in the International Autoimmune Hepatitis Group Retrospective Registry. The assessed clinical outcomes were HCC development, liver transplantation, and death. Fine and Gray regression analysis stratified by centre was applied to determine the effects of individual covariates; the cumulative incidence of HCC was estimated using the competing risk method with death as a competing risk. RESULTS: A total of 1,428 patients diagnosed with AIH from 1980 to 2020 from 22 eligible centres across Europe and Canada were included, with a median follow-up of 11.1 years (interquartile range 5.2-15.9). Two hundred and ninety-three (20.5%) patients had cirrhosis at diagnosis. During follow-up, 24 patients developed HCC (1.7%), an incidence rate of 1.44 cases/1,000 patient-years; the cumulative incidence of HCC increased over time (0.6% at 5 years, 0.9% at 10 years, 2.7% at 20 years, and 6.6% at 30 years of follow-up). Patients who developed cirrhosis during follow-up had a significantly higher incidence of HCC. The cumulative incidence of HCC was 2.6%, 4.6%, 5.6% and 6.6% at 5, 10, 15, and 20 years after the development of cirrhosis, respectively. Obesity (hazard ratio [HR] 2.94, p = 0.04), cirrhosis (HR 3.17, p = 0.01), and AIH/PSC variant syndrome (HR 5.18, p = 0.007) at baseline were independent risk factors for HCC development. CONCLUSIONS: HCC incidence in AIH is low even after cirrhosis development and is associated with risk factors including obesity, cirrhosis, and AIH/PSC variant syndrome. IMPACT AND IMPLICATIONS: The risk of developing hepatocellular carcinoma (HCC) in individuals with autoimmune hepatitis (AIH) seems to be lower than for other aetiologies of chronic liver disease. Yet, solid data for this specific patient group remain elusive, given that most of the existing evidence comes from small, single-centre studies. In our study, we found that HCC incidence in patients with AIH is low even after the onset of cirrhosis. Additionally, factors such as advanced age, obesity, cirrhosis, alcohol consumption, and the presence of the AIH/PSC variant syndrome at the time of AIH diagnosis are linked to a higher risk of HCC. Based on these findings, there seems to be merit in adopting a specialized HCC monitoring programme for patients with AIH based on their individual risk factors.
引用
- Colapietro F, Maisonneuve P, Lytvyak E, et al. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis. J Hepatol. 2023. PMID: 37802188. doi:10.1016/j.jhep.2023.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。